NCT00676221

Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)

Patient Reported Outcomes in Renal Transplant Patients Tolerating GI Symptoms Converted to Myfortic (EC-MPS).

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Foothills Medical Centre · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Hypothesis: Presently, some patients' mycophenolate mofetil (MMF.,Cellcept) related gastrointestinal (GI) symptoms are not being spontaneously reported. It is postulated that a conversion to enteric-coated mycophenolate sodium (EC-MPS.,Myfortic) from MMF will reduce the objectively measured GI symptom burden and improve GI-related quality of life. Primary Objective: To determine the incidence of GI-related symptoms and the health related quality of life of renal transplant patients that are currently tolerating MMF. Assessed by GSRS and GIQLI. Secondary Objective: To determine the impact on GI symptoms and the health related quality of life of renal transplant patients converted from MMF to Myfortic. Assessed by GSRS and GIQLI.

Detailed description

Investigator originated proposal. Single centre-Foothills Medical Centre, Southern Alberta Transplant Program. Study design: Three month, longitudinal, open-label, single arm study. Number of study visits: 3 (Baseline, 4-6 weeks, 12 weeks) Planned sample size :Approx. 110 subjects. Study population will be primary or secondary renal transplant recipients who are stable and are on maintenance immunosuppressive medication which includes MMF. Gastrointestinal rating scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI)will be the evaluation tool for GI symptoms, completed by study subject via a "touch screen" pc. at baseline, 4-6 week and final 12 week visit. Study subjects will discontinue MMF following the evening dose on the day of Baseline visit and commence EC-MPS at equimolar doses of subject's current MMF dose. At Final study visit (Week 12) study subject will be given the option of continuing on EC-MPS or resuming MMF. Endpoints: Primary: Incidence of patients tolerating MMF related GI symptoms. Secondary: 1. Patient reported symptoms and quality of life after conversion from MMF to EC-MPS. 2. Adverse events. 3. Renal function as determined by Cockroft-Gault equation 4. Routine hematological and chemistry bloodwork. Statistical consideration: Descriptive, pair T-Test analysis.

Conditions

• Kidney Transplant

Interventions

Type	Name	Description
DRUG	Myfortic	Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID. Cellcept 1000mg bid = Myfortic 720mg bid

Timeline

• Start date: 2006-07-01
• Primary completion: 2008-08-01
• Completion: 2008-09-01
• First posted: 2008-05-12
• Last updated: 2008-05-15

Locations

1 site across 1 country: Canada